US 9233117 B2 - Treatment Of Inflammatory Lesions Of Rosacea With Ivermectin - The Lens - Free & Open Patent and Scholarly Search

Patents

US 9233117 B2

Create Add Remove

Create New Collection

Make Note

Abstract

Methods for safe and effective treatment of inflammatory lesions of rosacea in a subject are described. The methods involve once daily topically applying to an affected skin area a topical composition containing ivermectin and a pharmaceutically acceptable carrier. It has been demonstrated that once daily topical treatment with ivermectin is significantly superior than twice-daily topical treatment with metronidazole in reducing inflammatory lesion counts.

Claims

A method of treating inflammatory lesions of rosacea in a subject in need thereof, comprising topically administering, once daily, to a skin area affected by the inflammatory lesions of rosacea a pharmaceutical composition comprising 1% by weight ivermectin and a pharmaceutically acceptable carrier, wherein as early as 2 weeks after the initial administration of the pharmaceutical composition, a significant reduction in inflammatory lesion count is observed.
The method of claim 1, wherein the treatment results in more reduction in inflammatory lesion count in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.
The method of claim 1, wherein the treatment results in longer relapse-free time of the inflammatory lesions of rosacea in the subject in comparison to that achieved by twice daily topically administering to the subject a second pharmaceutical composition comprising 0.75% by weight metronidazole.
The method of claim 1, wherein the treatment has a median time to first relapse of 110 days or longer.
The method of claim 1, wherein the subject has moderate to severe papulopustular rosacea before the treatment.
The method of claim 5, wherein the subject has 15 or more of the inflammatory lesions before the treatment.
The method of claim 1, wherein a steady state of plasma concentration of ivermectin is reached in the subject as early as 2 weeks after the initial administration of the pharmaceutical composition to the subject, wherein the steady state has a C_maxof ivermectin of 0.5-10 ng/mL, and an AUC_{0-24 hr}of 10-100 ng·hr/mL in the subject.
The method of claim 1, wherein the pharmaceutical composition further comprises one or more ingredients selected from the group consisting of: an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, the oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water.
The method of claim 1, wherein the topical administration of the pharmaceutical composition to the subject results in a mean terminal half-life of ivermectin of about 145 hours in the subject.
A method of treating inflammatory lesions of rosacea in a subject in need thereof, comprising topically administering, once daily, to a skin area affected by the inflammatory lesions a pharmaceutical composition comprising 1% by weight ivermectin and a pharmaceutically acceptable carrier, wherein as early as 2 weeks after the initial administration of the pharmaceutical composition to the subject, a significant reduction in inflammatory lesion count is observed and a steady state of plasma concentration of ivermectin is reached in the subject, and the steady state has a mean C_maxof ivermectin of 2.10±1.04 ng/mL with a range of 0.69-4.02 ng/mL, and a mean AUC_{0-24 hr}of 36.14±15.56 ng·hr/mL with a range of 13.69-75.16 ng·hr/mL.
The method of claim 10, wherein the treatment results in more reduction in inflammatory lesion count in the subject in comparison to that achieved by topically administering to the subject, twice daily, a second pharmaceutical composition comprising 0.75% by weight metronidazole.
The method of claim 10, wherein the treatment results in longer relapse-free time of the inflammatory lesions of rosacea in the subject in comparison to that achieved by twice daily topically administering to the subject a second pharmaceutical composition comprising 0.75% by weight metronidazole.
The method of claim 10, wherein the treatment has a median time to first relapse of 110 days or longer.
The method of claim 10, wherein the subject has moderate to severe papulopustular rosacea before the treatment.
The method of claim 14, wherein the subject has 15 or more of the inflammatory lesions before the treatment.
The method of claim 10, wherein the pharmaceutical composition further comprises one or more ingredients selected from the group consisting of: an oily phase comprising dimethicone, cyclomethicone, isopropyl palmitate and/or isopropyl myristate, the oily phase further comprising fatty substances selected from the group consisting of cetyl alcohol, cetostearyl alcohol, stearyl alcohol, palmitostearic acid, stearic acid and self-emulsifiable wax; at least one surfactant-emulsifier selected from the group consisting of glyceryl/PEG 100 stearate, sorbitan monostearate, sorbitan palmitate, Steareth-20, Steareth-2, Steareth-21 and Ceteareth-20; a mixture of solvents and/or propenetrating agents selected from the group consisting of propylene glycol, oleyl alcohol, phenoxyethanol and glyceryl triacetate; one or more gelling agents selected from the group consisting of carbomers, cellulose gelling agents, xanthan gums, aluminum magnesium silicates but excluding aluminum magnesium silicate/titanium dioxide/silica, guar gums, polyacrylamides and modified starches; and water.
The method of claim 10, wherein the pharmaceutical composition further comprises carbomer copolymer type B; cetyl alcohol; citric acid monohydrate; dimethicone 20 Cst; edetate disodium; glycerin; isopropyl palmitate; methyl paraben; oleyl alcohol; phenoxyethanol; polyoxyl 20 cetostearyl ether; propylene glycol; propyl paraben; purified water; sodium hydroxide; sorbitan monostearate and stearyl alcohol.
The method of claim 10, wherein the topical administration of the pharmaceutical composition to the subject results in a mean terminal half-life of ivermectin of about 145 hours in the subject.
The method of claim 10, wherein the treatment results in about 27% or more median reduction of the inflammatory lesion counts.

Owners (US)

Galderma S.a (Nov 05 2015)
Explore more patents:
- View all patents where Owners (US) GALDERMA S.A

Applicants

Galderma Sa
Explore more patents:
- View all patents where Applicants GALDERMA SA

Inventors

Jacovella Jean
Explore more patents:
- View all patents where Inventors JACOVELLA JEAN
- View all scholarly literature where Author = JACOVELLA JEAN
Chappuis Jean-paul
Explore more patents:
- View all patents where Inventors CHAPPUIS JEAN-PAUL
- View all scholarly literature where Author = CHAPPUIS JEAN-PAUL
Sordello Wagner Nathalie
Explore more patents:
- View all patents where Inventors SORDELLO WAGNER NATHALIE
- View all scholarly literature where Author = SORDELLO WAGNER NATHALIE
Graeber Michael
Explore more patents:
- View all patents where Inventors GRAEBER MICHAEL
- View all scholarly literature where Author = GRAEBER MICHAEL
Kaoukhov Alexandre
Explore more patents:
- View all patents where Inventors KAOUKHOV ALEXANDRE
- View all scholarly literature where Author = KAOUKHOV ALEXANDRE
Salin Laurence
Explore more patents:
- View all patents where Inventors SALIN LAURENCE
- View all scholarly literature where Author = SALIN LAURENCE
Poncet Michel
Explore more patents:
- View all patents where Inventors PONCET MICHEL
- View all scholarly literature where Author = PONCET MICHEL
Briantais Philippe
Explore more patents:
- View all patents where Inventors BRIANTAIS PHILIPPE
- View all scholarly literature where Author = BRIANTAIS PHILIPPE
Benkali Khaled
Explore more patents:
- View all patents where Inventors BENKALI KHALED
- View all scholarly literature where Author = BENKALI KHALED

CPC Classifications

A61K2300/00
Explore more patents:
- View all patents where CPC Classifications A61K2300/00
- View in Classification Explorer
A61K31/4164
Explore more patents:
- View all patents where CPC Classifications A61K31/4164
- View in Classification Explorer
A61K31/4174
Explore more patents:
- View all patents where CPC Classifications A61K31/4174
- View in Classification Explorer
A61K31/7048
Explore more patents:
- View all patents where CPC Classifications A61K31/7048
- View in Classification Explorer
A61K47/02
Explore more patents:
- View all patents where CPC Classifications A61K47/02
- View in Classification Explorer
A61K47/10
Explore more patents:
- View all patents where CPC Classifications A61K47/10
- View in Classification Explorer
A61K47/12
Explore more patents:
- View all patents where CPC Classifications A61K47/12
- View in Classification Explorer
A61K47/14
Explore more patents:
- View all patents where CPC Classifications A61K47/14
- View in Classification Explorer
A61K47/183
Explore more patents:
- View all patents where CPC Classifications A61K47/183
- View in Classification Explorer
A61K47/24
Explore more patents:
- View all patents where CPC Classifications A61K47/24
- View in Classification Explorer
A61K47/26
Explore more patents:
- View all patents where CPC Classifications A61K47/26
- View in Classification Explorer
A61K47/32
Explore more patents:
- View all patents where CPC Classifications A61K47/32
- View in Classification Explorer
A61K9/0014
Explore more patents:
- View all patents where CPC Classifications A61K9/0014
- View in Classification Explorer
A61K9/06
Explore more patents:
- View all patents where CPC Classifications A61K9/06
- View in Classification Explorer

IPC Classifications

A61K31/4164
Explore more patents:
- View all patents where IPC Classifications A61K31/4164
- View in Classification Explorer
A61K31/4174
Explore more patents:
- View all patents where IPC Classifications A61K31/4174
- View in Classification Explorer
A61K31/70
Explore more patents:
- View all patents where IPC Classifications A61K31/70
- View in Classification Explorer
A61K31/7048
Explore more patents:
- View all patents where IPC Classifications A61K31/7048
- View in Classification Explorer
A61K47/10
Explore more patents:
- View all patents where IPC Classifications A61K47/10
- View in Classification Explorer
A61K47/14
Explore more patents:
- View all patents where IPC Classifications A61K47/14
- View in Classification Explorer
A61K9/00
Explore more patents:
- View all patents where IPC Classifications A61K9/00
- View in Classification Explorer
A61K9/06
Explore more patents:
- View all patents where IPC Classifications A61K9/06
- View in Classification Explorer

Download PDF

Document Preview

Document History

Publication: Jan 12, 2016
US 9233117 B2
Application: Mar 13, 2014
US 201414209927 A
Priority: Mar 13, 2014
US 201414209927 A
Priority: Jan 15, 2014
US 201461927717 P
Priority: Dec 20, 2013
US 201361919208 P
Priority: Jul 8, 2013
US 201361843540 P